Dang, Nam H <br/><br/>
Phase II trial of the combination of denileukin diftitox and rituximab for relapsed/refractory B-cell non-Hodgkin lymphoma.  [electronic resource] 

 -  British journal of haematology  Aug 2007 
 - 502-5 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>0007-1048 
<br/><br/><label>Standard No.: </label>10.1111/j.1365-2141.2007.06684.x  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Antibodies, Monoclonal--therapeutic use<br/>Antibodies, Monoclonal, Murine-Derived<br/>Antineoplastic Combined Chemotherapy Protocols--therapeutic use<br/>Diphtheria Toxin--therapeutic use<br/>Female<br/>Humans<br/>Interleukin-2--therapeutic use<br/>Lymphoma, B-Cell--drug therapy<br/>Lymphoma, Follicular--drug therapy<br/>Male<br/>Middle Aged<br/>Neoplasm Staging<br/>Recombinant Fusion Proteins--therapeutic use<br/>Recurrence<br/>Rituximab<br/>Time Factors<br/>Treatment Outcome